Skyrizi Demonstrates Efficacy in Pediatric Psoriasis Treatment, FDA Approved for Children Aged 6 and Older
Rapid Read

Skyrizi Demonstrates Efficacy in Pediatric Psoriasis Treatment, FDA Approved for Children Aged 6 and Older

What's Happening? A recent Phase 3 study, published in the British Journal of Dermatology and reported by Dermatology Times, has shown promising results for Skyrizi (risankizumab) in treating moderate to severe plaque psoriasis in children and adolescents. The study included 137 patients aged 6 to 1
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.